var data={"title":"Cryptococcus neoformans infection outside the central nervous system","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Cryptococcus neoformans infection outside the central nervous system</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/contributors\" class=\"contributor contributor_credentials\">Gary M Cox, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/contributors\" class=\"contributor contributor_credentials\">John R Perfect, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/contributors\" class=\"contributor contributor_credentials\">Carol A Kauffman, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/contributors\" class=\"contributor contributor_credentials\">Sheldon L Kaplan, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/contributors\" class=\"contributor contributor_credentials\">Jennifer Mitty, MD, MPH</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Jul 24, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><em>Cryptococcus neoformans</em> pneumonia and infection outside the central nervous system in immunocompetent and immunocompromised patients will be reviewed here.</p><p>The microbiology and epidemiology of <em>C. neoformans</em> infection are presented separately. <em>C. neoformans</em> meningoencephalitis and <em>Cryptococcus gattii</em> infection are also discussed elsewhere. (See <a href=\"topic.htm?path=microbiology-and-epidemiology-of-cryptococcus-neoformans-infection\" class=\"medical medical_review\">&quot;Microbiology and epidemiology of Cryptococcus neoformans infection&quot;</a> and <a href=\"topic.htm?path=epidemiology-clinical-manifestations-and-diagnosis-of-cryptococcus-neoformans-meningoencephalitis-in-hiv-infected-patients\" class=\"medical medical_review\">&quot;Epidemiology, clinical manifestations, and diagnosis of Cryptococcus neoformans meningoencephalitis in HIV-infected patients&quot;</a> and <a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-cryptococcus-neoformans-meningoencephalitis-in-hiv-seronegative-patients\" class=\"medical medical_review\">&quot;Clinical manifestations and diagnosis of Cryptococcus neoformans meningoencephalitis in HIV-seronegative patients&quot;</a> and <a href=\"topic.htm?path=treatment-of-cryptococcus-neoformans-meningoencephalitis-in-hiv-infected-patients\" class=\"medical medical_review\">&quot;Treatment of Cryptococcus neoformans meningoencephalitis in HIV-infected patients&quot;</a> and <a href=\"topic.htm?path=cryptococcus-neoformans-treatment-of-meningoencephalitis-and-disseminated-infection-in-hiv-seronegative-patients\" class=\"medical medical_review\">&quot;Cryptococcus neoformans: Treatment of meningoencephalitis and disseminated infection in HIV seronegative patients&quot;</a> and <a href=\"topic.htm?path=cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis\" class=\"medical medical_review\">&quot;Cryptococcus gattii infection: Microbiology, epidemiology, and pathogenesis&quot;</a> and <a href=\"topic.htm?path=cryptococcus-gattii-infection-clinical-features-and-diagnosis\" class=\"medical medical_review\">&quot;Cryptococcus gattii infection: Clinical features and diagnosis&quot;</a> and <a href=\"topic.htm?path=cryptococcus-gattii-infection-treatment\" class=\"medical medical_review\">&quot;Cryptococcus gattii infection: Treatment&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">PULMONARY INFECTION IN IMMUNOCOMPETENT ADULTS</span></p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h2\">Clinical manifestations</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Humans likely become infected with <em>C. neoformans</em> by inhaling the basidiospore form of the fungus or small, poorly encapsulated yeasts. Basidiospores are smaller than the yeast forms obtained from clinical samples and have much smaller polysaccharide capsules, facilitating deposition in the alveoli and terminal bronchioles after inhalation [<a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/1\" class=\"abstract_t\">1</a>]. Following inhalation, <em>C. neoformans</em> likely cause a focal pneumonitis that may or may not be symptomatic. The immune status is the most important determinant of the subsequent course of the infection (eg, whether the pneumonitis resolves or progresses to symptomatic dissemination) [<a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/2,3\" class=\"abstract_t\">2,3</a>].</p><p>A large segment of the population has been exposed to <em>C. neoformans </em>[<a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/4\" class=\"abstract_t\">4</a>]. Subclinical primary infections are common and most are asymptomatic. Postmortem studies on immunocompetent persons without antecedent respiratory complaints have demonstrated small areas of granulomatous inflammation in the lung parenchyma <span class=\"nowrap\">and/or</span> hilar lymph nodes due to <em>C. neoformans</em> [<a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/5,6\" class=\"abstract_t\">5,6</a>]. The foci are generally smaller than those seen in tuberculosis and do not appear to calcify as frequently as seen with histoplasmosis. Infection can persist in a latent state; if the host immune system becomes compromised, organisms may be liberated from the granulomatous complexes and cause active infection.</p><p>There are also descriptions of pulmonary cryptococcosis in apparently immunocompetent patients [<a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/7,8\" class=\"abstract_t\">7,8</a>]. In a review of approximately 90 immunocompetent hosts with pulmonary cryptococcosis, 32 percent of the patients were asymptomatic, and pulmonary infection was discovered as an incidental finding [<a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/7\" class=\"abstract_t\">7</a>]. Asymptomatic patients with chest radiograph findings suspicious for malignancy who undergo biopsy are occasionally found to have cryptococcosis.</p><p>The factors that determine whether an exposed person develops symptomatic infection are uncertain but may include the inoculum of fungi (eg, burden of exposure) <span class=\"nowrap\">and/or</span> virulence factors of the infecting strain. Common symptoms include cough, sputum production, hemoptysis, dyspnea, chest pain, fever, malaise, night sweats, and weight loss [<a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/7,9-11\" class=\"abstract_t\">7,9-11</a>]. Less common symptoms include rash and gastrointestinal complaints. Rare manifestations include obstruction of the superior vena cava, Pancoast syndrome due to granulomatous inflammation from the host response to <em>C. neoformans</em>, eosinophilic pneumonia, and extension from the lung to the chest wall [<a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/12-15\" class=\"abstract_t\">12-15</a>].</p><p class=\"headingAnchor\" id=\"H4\"><span class=\"h2\">Diagnosis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Diagnostic tools for pulmonary cryptococcosis include histology, fungal culture, serum cryptococcal antigen, and radiography.</p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h3\">Culture and histology</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Visualization of encapsulated yeast forms in sputum, bronchoalveolar lavage or tissue specimens is suggestive of cryptococcal pulmonary infection. The diagnosis is established by culturing the organism from sputum or another specimen. Biopsy specimens of asymptomatic nodules may have yeast on histopathologic inspection but the culture may be negative.</p><p>Associated pleural effusions are usually exudative [<a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/16,17\" class=\"abstract_t\">16,17</a>]. Yeast forms may be seen in the pleural effusion, and cultures are usually positive.</p><p>Routine blood cultures are appropriate for patients who have extensive infiltrates <span class=\"nowrap\">and/or</span> systemic symptoms.</p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h3\">Cryptococcal antigen</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Serum cryptococcal antigen should be performed. Although positive results are often found in immunocompromised hosts with <em>C. neoformans </em>pneumonia, antigen detection is not a sensitive test for diagnosis of pulmonary infection in immunocompetent patients. However, antigen testing may be more useful for diagnosis of cryptococcal pneumonia due to <em>C. gattii</em> among immunocompetent hosts in regions where <em>C. gattii</em> is endemic (eg, Australia) or has caused outbreaks of disease (eg, the United States Pacific Northwest and British Columbia). (See <a href=\"topic.htm?path=cryptococcus-gattii-infection-clinical-features-and-diagnosis#H12417225\" class=\"medical medical_review\">&quot;Cryptococcus gattii infection: Clinical features and diagnosis&quot;, section on 'Cryptococcal antigen'</a>.)</p><p>There is no role for monitoring serum cryptococcal antigen titers to determine duration of therapy in either immunosuppressed or immunocompetent hosts.</p><p class=\"headingAnchor\" id=\"H7\"><span class=\"h3\">Radiography</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Radiographic features of pulmonary cryptococcosis in immunocompetent patients are variable. The most common findings are solitary or few well-defined, noncalcified nodules that are often pleural based (<a href=\"image.htm?imageKey=ID%2F64815\" class=\"graphic graphic_diagnosticimage graphicRef64815 \">image 1</a>) [<a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/18-20\" class=\"abstract_t\">18-20</a>]. Other radiographic findings include lobar infiltrates, hilar and mediastinal adenopathy, and pleural effusions [<a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/16,17,21-24\" class=\"abstract_t\">16,17,21-24</a>]. In a case series of 12 immunocompetent hosts, 10 patients had nodules and masses (eight were peripheral); three had cavitation [<a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/25\" class=\"abstract_t\">25</a>].</p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h3\">Lumbar puncture</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Dissemination from the lungs to the central nervous system (CNS) in immunocompetent patients is rare, and routine lumbar puncture to evaluate for cryptococcal meningoencephalitis is generally not necessary [<a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/26\" class=\"abstract_t\">26</a>]. Immunocompetent hosts with no CNS symptoms and low serum cryptococcal antigen titer (&lt;1:512) need not undergo lumbar puncture. However, lumbar puncture is warranted for patients with neurologic symptoms or an underlying condition that predisposes to dissemination. Lumbar puncture is also appropriate for immunocompetent patients with a very high serum cryptococcal antigen titer (&gt;1:512); such patients appear to have a higher burden of infection with risk for extrapulmonary spread and seeding of the central nervous system.</p><p class=\"headingAnchor\" id=\"H9\"><span class=\"h2\">Treatment</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The goal of treatment is to control signs and symptoms of cryptococcal pneumonia and minimize risk of dissemination to the central nervous system [<a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/27\" class=\"abstract_t\">27</a>]. Literature for management of pulmonary cryptococcal infection consists of retrospective reports; the approach is extrapolated from literature describing management of patients with HIV infection and CNS disease [<a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/9,28-31\" class=\"abstract_t\">9,28-31</a>].</p><p>Pleural effusions rarely require drainage [<a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/16,17\" class=\"abstract_t\">16,17</a>]. Surgical excision of infected pulmonary tissue is only indicated in cases of masses that impinge on adjacent structures [<a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/12,13\" class=\"abstract_t\">12,13</a>].</p><p>The management of <em>C. gattii</em> infection is discussed separately. (See <a href=\"topic.htm?path=cryptococcus-gattii-infection-treatment\" class=\"medical medical_review\">&quot;Cryptococcus gattii infection: Treatment&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H10\"><span class=\"h3\">Antifungal therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patients with severe pulmonary disease (eg, diffuse pulmonary infiltrates) or disseminated disease (eg, at least two noncontiguous sites) or a cryptococcal antigen titer &ge;1:512 (a known poor prognostic factor [<a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/32\" class=\"abstract_t\">32</a>]) should be managed as outlined separately. (See <a href=\"topic.htm?path=cryptococcus-neoformans-treatment-of-meningoencephalitis-and-disseminated-infection-in-hiv-seronegative-patients\" class=\"medical medical_review\">&quot;Cryptococcus neoformans: Treatment of meningoencephalitis and disseminated infection in HIV seronegative patients&quot;</a>.)</p><p>Based on extrapolation from literature describing management of patients with HIV infection, treatment for immunocompetent patients with mild to moderate pulmonary cryptococcosis in the absence of diffuse pulmonary infiltrates or disseminated infection consists of <a href=\"topic.htm?path=fluconazole-drug-information\" class=\"drug drug_general\">fluconazole</a> (400 mg [6 <span class=\"nowrap\">mg/kg]</span> orally daily ) for 6 to 12 months (<a href=\"image.htm?imageKey=ID%2F82028\" class=\"graphic graphic_table graphicRef82028 \">table 1</a>) [<a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/27\" class=\"abstract_t\">27</a>]. If fluconazole is not available or is contraindicated, acceptable alternatives include: <a href=\"topic.htm?path=itraconazole-drug-information\" class=\"drug drug_general\">itraconazole</a> (loading doses of 200 mg orally three times daily for three days, then 200 mg orally twice daily); <a href=\"topic.htm?path=voriconazole-drug-information\" class=\"drug drug_general\">voriconazole</a> (loading doses of 6 <span class=\"nowrap\">mg/kg</span> intravenously [IV] twice daily or 400 mg orally twice daily on the first day, then 200 mg orally twice daily); <a href=\"topic.htm?path=posaconazole-drug-information\" class=\"drug drug_general\">posaconazole</a> delayed-release tablets (loading doses of 300 mg orally twice daily on the first day, then 300 mg orally once daily); or <a href=\"topic.htm?path=isavuconazole-isavuconazonium-sulfate-drug-information\" class=\"drug drug_general\">isavuconazole</a> (200 mg three times per day for two days, then 200 mg orally once daily) [<a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/33\" class=\"abstract_t\">33</a>], although there are minimal data available regarding the latter agents.</p><p>Asymptomatic patients who have cryptococcal infection diagnosed incidentally in the setting of pulmonary nodule resection to rule out malignancy and who have negative cultures and cryptococcal antigen titers may not require antifungal therapy. There are reports of immunocompetent, asymptomatic patients with positive culture, serology, <span class=\"nowrap\">and/or</span> histopathology who improved radiographically with observation alone in the absence of antifungal therapy [<a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/9,29,31\" class=\"abstract_t\">9,29,31</a>].</p><p>Asymptomatic patients with detectable serum cryptococcal antigen probably have a very low likelihood of symptomatic systemic dissemination. However, treatment with <a href=\"topic.htm?path=fluconazole-drug-information\" class=\"drug drug_general\">fluconazole</a> is appropriate since it is likely to be curative and the risk of adverse effects is low [<a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/27\" class=\"abstract_t\">27</a>].</p><p>There is no role for monitoring serum cryptococcal antigen titers to guide duration of therapy.</p><p class=\"headingAnchor\" id=\"H1029509529\"><span class=\"h3\">Surgery</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Occasionally, localized cryptococcal infections of the lung not responding to medical therapy may need surgical resection for cure [<a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/27\" class=\"abstract_t\">27</a>].</p><p class=\"headingAnchor\" id=\"H11\"><span class=\"h1\">PULMONARY INFECTION IN IMMUNOCOMPROMISED ADULTS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Most cases of pulmonary cryptococcosis in the immunocompromised host are likely due to reactivation of latent infection. However, primary infection in a na&iuml;ve host or reinfection with a new strain is also possible. Immunocompromised hosts with pulmonary cryptococcosis generally have more symptoms than immunocompetent hosts and are more likely to present with extrapulmonary disease.</p><p>Conditions that increase risk for pulmonary cryptococcosis include HIV infection, malignancies, stem cell and solid organ transplantation, cirrhosis, renal failure, chronic lung disease, diabetes, Cushing's syndrome, sarcoidosis, and treatment with glucocorticoids or tumor necrosis factor-alpha antagonists [<a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/9,31,34-40\" class=\"abstract_t\">9,31,34-40</a>]. Cryptococcal pneumonia in a lung transplant patient due to asymptomatic <em>C. neoformans</em> carriage in the donor lung has also been reported [<a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/41\" class=\"abstract_t\">41</a>].</p><p class=\"headingAnchor\" id=\"H12\"><span class=\"h2\">Clinical manifestations</span></p><p class=\"headingAnchor\" id=\"H13\"><span class=\"h3\">HIV-negative patients</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Clinical manifestations due to pulmonary cryptococcosis range from asymptomatic pneumonia to acute respiratory failure [<a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/9,28,31,42\" class=\"abstract_t\">9,28,31,42</a>]. Among 34 immunocompromised patients with cryptococcal pneumonia, 28 developed extrapulmonary disease [<a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/31\" class=\"abstract_t\">31</a>]. The most common symptoms were fever (63 percent), chest pain (44 percent), dyspnea (27 percent), cough (17 percent), and hemoptysis (7 percent).</p><p>Cryptococcal pneumonia and acute respiratory distress syndrome (ARDS) occur more frequently among organ transplant recipients than other hosts [<a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/28,43,44\" class=\"abstract_t\">28,43,44</a>]. In this setting, ARDS is often associated with disseminated infection; mortality is high and urgent treatment is required [<a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/28,42\" class=\"abstract_t\">28,42</a>]. Such patients should be managed as outlined separately for cryptococcal meningoencephalitis. (See <a href=\"topic.htm?path=cryptococcus-neoformans-treatment-of-meningoencephalitis-and-disseminated-infection-in-hiv-seronegative-patients\" class=\"medical medical_review\">&quot;Cryptococcus neoformans: Treatment of meningoencephalitis and disseminated infection in HIV seronegative patients&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H14\"><span class=\"h3\">HIV-positive patients</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The presentation of pulmonary cryptococcosis in patients with HIV is more acute and severe than in other hosts. The severity of symptoms and extent of dissemination are inversely proportional to the CD4 lymphocyte count; most symptomatic cases occur in patients with CD4 counts less than <span class=\"nowrap\">100/microL</span>.</p><p>Clinical manifestations include fever (81 to 94 percent), cough (63 to 71 percent), dyspnea (5 to 50 percent), and headache (41 percent) [<a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/38\" class=\"abstract_t\">38</a>]. Some patients are hypoxic; some present with ARDS. Dissemination from the lungs to the central nervous system occurs in 65 to 94 percent of cases of HIV-associated pulmonary cryptococcosis [<a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/30,38,45,46\" class=\"abstract_t\">30,38,45,46</a>].</p><p>Other opportunistic infections with manifestations similar to pulmonary cryptococcosis include those due to <em>Pneumocystis jirovecii</em>, <em>Mycobacterium avium</em> complex, <em>Mycobacterium tuberculosis</em>, cytomegalovirus, and <em>Histoplasma capsulatum</em> [<a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/38,46\" class=\"abstract_t\">38,46</a>].</p><p class=\"headingAnchor\" id=\"H15\"><span class=\"h2\">Diagnosis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Diagnostic tools for pulmonary cryptococcosis include histology, fungal culture, serum cryptococcal antigen, and radiography.</p><p>Evaluation of immunocompromised patients with pulmonary cryptococcosis should include evaluation for disseminated infection; this includes blood and cerebrospinal fluid (CSF) cultures as well as blood and CSF cryptococcal polysaccharide antigen testing [<a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/32\" class=\"abstract_t\">32</a>].</p><p class=\"headingAnchor\" id=\"H16\"><span class=\"h3\">Cryptococcal antigen</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The serum cryptococcal antigen is positive in virtually all patients with HIV infection and pulmonary cryptococcosis and in 56 to 70 percent of patients with other underlying immunocompromising conditions [<a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/9,30,36,37,47\" class=\"abstract_t\">9,30,36,37,47</a>]. Therefore, it is an excellent screening test in immunocompromised patients with respiratory symptoms. False-positive serum cryptococcal antigen tests can occur in the setting of infections due to the fungus <em>Trichosporon asahii</em> (formerly <em>T. beigelii</em>) or the bacterial genera <em>Stomatococcus </em>or <em>Capnocytophaga </em>[<a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/48-50\" class=\"abstract_t\">48-50</a>]. False-negative serum cryptococcal antigen tests can occur with samples that contain a large amount of antigen (the prozone phenomenon) if the laboratory is using a latex agglutination assay and doesn't pretreat the sample with pronase [<a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/51\" class=\"abstract_t\">51</a>].</p><p>In solid organ transplant recipients with pulmonary cryptococcosis, a positive serum cryptococcal antigen test frequently reflects advanced lung involvement <span class=\"nowrap\">and/or</span> extrapulmonary disease, such as fungemia or central nervous system infection [<a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/52\" class=\"abstract_t\">52</a>]. In one series including solid organ transplant recipients, a positive serum cryptococcal antigen titer was documented in 38 percent of patients with pulmonary cryptococcosis [<a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/29\" class=\"abstract_t\">29</a>]. In a prospective study of 60 solid organ transplant recipients with pulmonary cryptococcosis, positive serum cryptococcal antigen results were observed in 84 percent of those with any pulmonary involvement; the test was positive in 73 percent of those with disease limited to the lungs [<a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/52\" class=\"abstract_t\">52</a>]. However, a negative cryptococcal antigen result does not exclude the diagnosis of cryptococcosis.</p><p>Given the high rate of extrapulmonary disease among immunocompromised patients with cryptococcal pneumonia, a positive serum cryptococcal antigen result should prompt investigation for disseminated infection with blood culture, CSF cryptococcal antigen assay, and CSF culture [<a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/32\" class=\"abstract_t\">32</a>]. Positive results should prompt management as outlined separately. (See <a href=\"topic.htm?path=cryptococcus-neoformans-treatment-of-meningoencephalitis-and-disseminated-infection-in-hiv-seronegative-patients\" class=\"medical medical_review\">&quot;Cryptococcus neoformans: Treatment of meningoencephalitis and disseminated infection in HIV seronegative patients&quot;</a> and <a href=\"topic.htm?path=epidemiology-clinical-manifestations-and-diagnosis-of-cryptococcus-neoformans-meningoencephalitis-in-hiv-infected-patients\" class=\"medical medical_review\">&quot;Epidemiology, clinical manifestations, and diagnosis of Cryptococcus neoformans meningoencephalitis in HIV-infected patients&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H17\"><span class=\"h3\">Culture and histology</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Culture of expectorated sputum samples is often positive in immunocompromised patients. <em>C. neoformans</em> in respiratory tract specimens from transplant patients should be considered to represent a true pathogen. Bronchoscopy may be indicated in patients with advanced HIV infection to rule out other opportunistic infections [<a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/53\" class=\"abstract_t\">53</a>].</p><p>Biopsy is necessary only if malignancy is suspected. Histology can help to establish the diagnosis by demonstrating encapsulated yeast forms (<a href=\"image.htm?imageKey=ID%2F64561\" class=\"graphic graphic_picture graphicRef64561 \">picture 1</a>).</p><p>Routine blood cultures are appropriate for patients with severe immunosuppression, extensive infiltrates, <span class=\"nowrap\">and/or</span> systemic symptoms.</p><p class=\"headingAnchor\" id=\"H18\"><span class=\"h3\">Radiography</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Radiographic findings are usually more severe than those seen in apparently immunocompetent patients. (See <a href=\"#H7\" class=\"local\">'Radiography'</a> above.)</p><p>In patients with HIV, alveolar infiltrates, lymphadenopathy, mass lesions, and small pleural effusions have been described [<a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/38\" class=\"abstract_t\">38</a>]. Interstitial infiltrates may mimic the radiographic presentation of <em>P. jirovecii</em> pneumonia [<a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/38,54\" class=\"abstract_t\">38,54</a>]. (See <a href=\"topic.htm?path=clinical-presentation-and-diagnosis-of-pneumocystis-pulmonary-infection-in-hiv-infected-patients\" class=\"medical medical_review\">&quot;Clinical presentation and diagnosis of Pneumocystis pulmonary infection in HIV-infected patients&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H19\"><span class=\"h3\">Lumbar puncture</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Lumbar puncture to evaluate for cryptococcal meningoencephalitis is warranted for patients with neurologic symptoms or an underlying condition that predisposes to dissemination. In a study of HIV-seronegative patients with pulmonary cryptococcal disease, those with disseminated disease were more likely to have cirrhosis, headache, weight loss, fever, altered mental status, <span class=\"nowrap\">and/or</span> to be receiving high-dose glucocorticoids [<a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/26\" class=\"abstract_t\">26</a>].</p><p>Although the definition of the immunocompromised state is imprecise, a lumbar puncture to rule out central nervous system disease should be performed in those with pulmonary cryptococcosis who are considered to be immunosuppressed even in the absence of neurologic signs or symptoms. Such patients appear to have a higher burden of infection with risk for extrapulmonary spread and seeding of the central nervous system. (See <a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-cryptococcus-neoformans-meningoencephalitis-in-hiv-seronegative-patients\" class=\"medical medical_review\">&quot;Clinical manifestations and diagnosis of Cryptococcus neoformans meningoencephalitis in HIV-seronegative patients&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H20\"><span class=\"h2\">Treatment</span></p><p class=\"headingAnchor\" id=\"H21\"><span class=\"h3\">Antifungal therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patients with severe pulmonary disease (eg, diffuse pulmonary infiltrates) or disseminated disease (eg, at least two noncontiguous sites) or a serum cryptococcal antigen titer &ge;1:512 (a known poor prognostic factor [<a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/32\" class=\"abstract_t\">32</a>]) should be managed as outlined separately. (See <a href=\"topic.htm?path=cryptococcus-neoformans-treatment-of-meningoencephalitis-and-disseminated-infection-in-hiv-seronegative-patients\" class=\"medical medical_review\">&quot;Cryptococcus neoformans: Treatment of meningoencephalitis and disseminated infection in HIV seronegative patients&quot;</a>.)</p><p>The optimal treatment of cryptococcal pneumonia is uncertain; management is extrapolated from literature describing management of patients with HIV infection and central nervous system disease [<a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/9,29,30\" class=\"abstract_t\">9,29,30</a>]. In general, treatment for immunocompromised patients with mild to moderate pulmonary cryptococcosis in the absence of diffuse pulmonary infiltrates or disseminated infection consists of <a href=\"topic.htm?path=fluconazole-drug-information\" class=\"drug drug_general\">fluconazole</a> (400 mg [6 <span class=\"nowrap\">mg/kg]</span> orally daily) for 6 to 12 months (<a href=\"image.htm?imageKey=ID%2F82028\" class=\"graphic graphic_table graphicRef82028 \">table 1</a>) [<a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/27\" class=\"abstract_t\">27</a>]. If fluconazole is not available or contraindicated, acceptable alternatives include: <a href=\"topic.htm?path=itraconazole-drug-information\" class=\"drug drug_general\">itraconazole</a> (loading doses of 200 mg orally three times daily for three days, then 200 mg orally twice daily); <a href=\"topic.htm?path=voriconazole-drug-information\" class=\"drug drug_general\">voriconazole</a> (loading doses of 6 <span class=\"nowrap\">mg/kg</span> intravenously twice daily or 400 mg orally twice daily on the first day, then 200 mg orally twice daily); <a href=\"topic.htm?path=posaconazole-drug-information\" class=\"drug drug_general\">posaconazole</a> delayed-release tables (loading doses of 300 mg orally twice daily on the first day, then 300 mg orally once daily) [<a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/55,56\" class=\"abstract_t\">55,56</a>]; or <a href=\"topic.htm?path=isavuconazole-isavuconazonium-sulfate-drug-information\" class=\"drug drug_general\">isavuconazole</a> (200 mg three times per day for two days, then 200 mg once per day) [<a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/33\" class=\"abstract_t\">33</a>], although there are minimal data for the latter agents.</p><p>The efficacy of this approach was illustrated in a study of 39 solid organ transplant recipients with extraneural cryptococcosis who received <a href=\"topic.htm?path=fluconazole-drug-information\" class=\"drug drug_general\">fluconazole</a> or a regimen containing amphotericin B; the mortality was comparable (10 to 11 percent) [<a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/57\" class=\"abstract_t\">57</a>]. Among 109 HIV-negative immunocompromised patients with pulmonary cryptococcosis treated with fluconazole, the 12-month survival was 95 percent [<a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/9\" class=\"abstract_t\">9</a>]. In a retrospective review of 14 solid organ transplant recipients with extraneural cryptococcosis who received fluconazole as primary therapy for a median of 60 days, no therapeutic failures were observed [<a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/57\" class=\"abstract_t\">57</a>].</p><p>HIV-infected patients should continue chronic suppressive therapy with 200 mg per day of <a href=\"topic.htm?path=fluconazole-drug-information\" class=\"drug drug_general\">fluconazole</a>. In patients with HIV who are receiving highly active antiretroviral therapy and have CD4 count &gt;100 <span class=\"nowrap\">cells/microL,</span> suppressed viral load, and a cryptococcal antigen titer &le;1:512 that is not increasing, it may be reasonable to discontinue maintenance fluconazole after one year of treatment [<a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/58\" class=\"abstract_t\">58</a>].</p><p>Patients who have responded to therapy for pulmonary cryptococcosis and subsequently must undergo chemotherapy or intensive therapy for graft rejection within two years of the diagnosis should be treated with <a href=\"topic.htm?path=fluconazole-drug-information\" class=\"drug drug_general\">fluconazole</a> while receiving such therapy to prevent recurrent cryptococcal infection.</p><p>There is no role for monitoring serum cryptococcal antigen titers to determine duration of therapy.</p><p class=\"headingAnchor\" id=\"H951399052\"><span class=\"h3\">Surgery</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Occasionally, localized cryptococcal infections of the lung not responding to medical therapy may need surgical resection for cure [<a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/27\" class=\"abstract_t\">27</a>].</p><p class=\"headingAnchor\" id=\"H24\"><span class=\"h1\">PULMONARY INFECTION IN PREGNANT WOMEN</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There have been cases of cryptococcal pneumonia described in pregnancy, although there are insufficient epidemiologic data to implicate pregnancy as a predisposing condition [<a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/59\" class=\"abstract_t\">59</a>].</p><p>Patients with severe pulmonary disease (eg, diffuse pulmonary infiltrates) or disseminated disease (eg, at least two noncontiguous sites or cryptococcal antigen titer &ge;1:512) should be managed as outlined separately. </p><p>Pregnant women with stable pulmonary cryptococcosis should be followed closely, and therapy with <a href=\"topic.htm?path=fluconazole-drug-information\" class=\"drug drug_general\">fluconazole</a> can begin following delivery [<a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/27\" class=\"abstract_t\">27</a>]. Immune reconstitution inflammatory syndrome can occur in the postpartum period [<a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/60-62\" class=\"abstract_t\">60-62</a>]. Indeed, nearly half of the <em>Cryptococcus </em>cases reported in pregnancy presented with symptomatic disease in the third trimester or postpartum period [<a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/59\" class=\"abstract_t\">59</a>]. (See <a href=\"topic.htm?path=immune-reconstitution-inflammatory-syndrome\" class=\"medical medical_review\">&quot;Immune reconstitution inflammatory syndrome&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H25\"><span class=\"h1\">PULMONARY INFECTION IN CHILDREN</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><em>Cryptococcus </em>has been reported in children with primary immunodeficiencies such as hyperimmunoglobulin M syndrome and severe combined immunodeficiency syndrome, as well as children with HIV, connective tissue diseases, and solid organ transplant recipients. Cryptococcosis has also been described in children with no recognized immunodeficiency.</p><p>Patients with severe pulmonary disease (eg, diffuse pulmonary infiltrates) or disseminated disease (eg, at least two noncontiguous sites or serum cryptococcal antigen titer &ge;1:512) should be managed as outlined separately. </p><p>Treatment of children with mild to moderate pulmonary cryptococcosis consists of <a href=\"topic.htm?path=fluconazole-drug-information\" class=\"drug drug_general\">fluconazole</a> (6 to 12 <span class=\"nowrap\">mg/kg</span> per day orally) for 6 to 12 months [<a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/27\" class=\"abstract_t\">27</a>].</p><p class=\"headingAnchor\" id=\"H26\"><span class=\"h1\">NONMENINGEAL, NONPULMONARY CRYPTOCOCCOSIS</span></p><p class=\"headingAnchor\" id=\"H27\"><span class=\"h2\">Clinical manifestations</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Nonmeningeal, nonpulmonary cryptococcosis generally reflects disseminated infection, even if clinical manifestations are confined to a single anatomic site (such as skin, soft tissue, or osteoarticular infection).</p><p>Cryptococcal skin lesions are seen in up to 15 percent of patients with disseminated infection; they manifest as papules (<a href=\"image.htm?imageKey=DERM%2F69214\" class=\"graphic graphic_picture graphicRef69214 \">picture 2</a>), plaques, purpura, ulcers, cellulitis, superficial plaques, abscesses, and sinus tracts [<a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/63,64\" class=\"abstract_t\">63,64</a>]. Patients with advanced HIV infection may have umbilicated papules resembling molluscum contagiosum; in transplant patients, cellulitis may occur without evidence of dissemination. Although the majority of cryptococcal skin lesions result from disseminated infection, primary cryptococcal skin infections by direct inoculation may occur [<a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/65\" class=\"abstract_t\">65</a>].</p><p>Cryptococcal lesions of the skeletal system occur in &lt;10 percent of patients with disseminated disease [<a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/66\" class=\"abstract_t\">66</a>]. The vertebrae are the most common site of osteoarticular infection. Radiography typically demonstrates a well-circumscribed osteolytic lesion resembling malignancy. Septic arthritis is rare.</p><p>Cryptococcal infection can involve any body site or structure following dissemination, including the liver, lymph nodes, peritoneum, urogenital tract, adrenal glands, and eyes. Involvement of the eyes frequently reflects central nervous system (CNS) infection, which should be sought in all cases [<a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/67\" class=\"abstract_t\">67</a>]. The prostate may serve as a reservoir of infection [<a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/68\" class=\"abstract_t\">68</a>]. (See <a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-cryptococcus-neoformans-meningoencephalitis-in-hiv-seronegative-patients\" class=\"medical medical_review\">&quot;Clinical manifestations and diagnosis of Cryptococcus neoformans meningoencephalitis in HIV-seronegative patients&quot;</a>.)</p><p>Among 175 solid organ transplant recipients with cryptococcosis, nine patients (5 percent) presented very early following transplantation (defined as &le;30 days post-transplant; mean 5.7 days post-transplant) [<a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/69\" class=\"abstract_t\">69</a>]. Patients who presented very early were more likely to have disease at unusual locations, including in the transplanted allograft or in the surgical fossa. These locations suggest that the infections were donor derived. Five of the nine patients (56 percent) with very early&ndash;onset disease were liver transplant recipients compared with 43 of 166 patients (26 percent) with disease occurring &gt;30 days post transplant [<a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/69\" class=\"abstract_t\">69</a>], suggesting that some of these patients may have had unrecognized infection prior to transplantation as a result of the impaired host defenses that accompany cirrhosis [<a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/70\" class=\"abstract_t\">70</a>].</p><p class=\"headingAnchor\" id=\"H28\"><span class=\"h2\">Treatment</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patients with severe pulmonary disease (eg, diffuse pulmonary infiltrates) or disseminated disease (eg, at least two noncontiguous sites or cryptococcal antigen titer &ge;1:512) should be managed as outlined separately. (See <a href=\"topic.htm?path=cryptococcus-neoformans-treatment-of-meningoencephalitis-and-disseminated-infection-in-hiv-seronegative-patients\" class=\"medical medical_review\">&quot;Cryptococcus neoformans: Treatment of meningoencephalitis and disseminated infection in HIV seronegative patients&quot;</a>.)</p><p>There are no studies evaluating treatment of cryptococcal infection involving sites other than lungs and CNS. In general, infection at a single site in the absence of CNS disease, fungemia or risk factors for immunosuppression may be managed with <a href=\"topic.htm?path=fluconazole-drug-information\" class=\"drug drug_general\">fluconazole</a> (400 mg [6 <span class=\"nowrap\">mg/kg]</span> orally once daily) for 6 to 12 months [<a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/27,71,72\" class=\"abstract_t\">27,71,72</a>].</p><p>Management of ocular infections must be managed in consultation with ophthalmologic expertise and tailored to individual circumstances depending on the extent of eye structure involvement and whether CNS involvement has been documented. Therapeutic possibilities include systemic therapy with high penetration into the eye such as <a href=\"topic.htm?path=fluconazole-drug-information\" class=\"drug drug_general\">fluconazole</a> or <a href=\"topic.htm?path=flucytosine-drug-information\" class=\"drug drug_general\">flucytosine</a> <span class=\"nowrap\">and/or</span> adjunctive intravitreal <a href=\"topic.htm?path=amphotericin-b-deoxycholate-conventional-drug-information\" class=\"drug drug_general\">amphotericin B deoxycholate</a>.</p><p class=\"headingAnchor\" id=\"H29\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A large segment of the population has been exposed to <em>Cryptococcus neoformans</em>. Subclinical primary infections are common, and most are asymptomatic. Infection can persist in a latent state; if the host immune system becomes compromised, organisms may be liberated from the granulomatous complexes and cause active infection. Symptomatic pulmonary cryptococcosis can also occur in apparently immunocompetent patients. (See <a href=\"#H2\" class=\"local\">'Pulmonary infection in immunocompetent adults'</a> above and <a href=\"#H11\" class=\"local\">'Pulmonary infection in immunocompromised adults'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Clinical manifestations due to cryptococcal pneumonia range from asymptomatic pneumonia to acute respiratory failure. The presentation of pulmonary cryptococcosis in patients with HIV is more acute and severe than in other hosts. Most symptomatic cases occur in patients with CD4 counts less than 100 <span class=\"nowrap\">cells/microL</span>. (See <a href=\"#H14\" class=\"local\">'HIV-positive patients'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The diagnosis of cryptococcal pneumonia in immunocompetent hosts is established by culturing the organism from sputum or another specimen. Visualization of encapsulated yeast forms in sputum, bronchoalveolar lavage, or tissue specimens is suggestive of cryptococcal pulmonary infection. The most common radiographic findings are solitary or few well-defined, noncalcified nodules. Lumbar puncture is warranted for patients with neurologic symptoms and for patients with serum cryptococcal antigen titer &gt;1:512. (See <a href=\"#H4\" class=\"local\">'Diagnosis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The serum cryptococcal antigen titer is often positive in immunocompromised patients with cryptococcal pneumonia. Culture of respiratory specimens is also a useful tool. A lumbar puncture to rule out central nervous system disease should be performed in those with pulmonary cryptococcosis who are considered to be immunosuppressed even in the absence of neurologic signs or symptoms.(See <a href=\"#H15\" class=\"local\">'Diagnosis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>We suggest that patients with mild to moderate pulmonary cryptococcosis in the absence of diffuse pulmonary infiltrates or disseminated infection be treated with <a href=\"topic.htm?path=fluconazole-drug-information\" class=\"drug drug_general\">fluconazole</a> (<a href=\"grade.htm?i=5\" class=\"grade\">Grade 2B</a>). Dosing is fluconazole 400 mg (6 <span class=\"nowrap\">mg/kg)</span> orally once daily for 6 to 12 months (<a href=\"image.htm?imageKey=ID%2F82028\" class=\"graphic graphic_table graphicRef82028 \">table 1</a>). (See <a href=\"#H10\" class=\"local\">'Antifungal therapy'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Patients with severe pulmonary disease (eg, diffuse pulmonary infiltrates) or disseminated disease (eg, at least two noncontiguous sites or cryptococcal antigen titer &ge;1:512) should be managed as outlined separately. (See <a href=\"topic.htm?path=cryptococcus-neoformans-treatment-of-meningoencephalitis-and-disseminated-infection-in-hiv-seronegative-patients\" class=\"medical medical_review\">&quot;Cryptococcus neoformans: Treatment of meningoencephalitis and disseminated infection in HIV seronegative patients&quot;</a>.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/1\" class=\"nounderline abstract_t\">Velagapudi R, Hsueh YP, Geunes-Boyer S, et al. Spores as infectious propagules of Cryptococcus neoformans. Infect Immun 2009; 77:4345.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/2\" class=\"nounderline abstract_t\">Salkowski CA, Balish E. Role of natural killer cells in resistance to systemic cryptococcosis. J Leukoc Biol 1991; 50:151.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/3\" class=\"nounderline abstract_t\">Huffnagle GB, Traynor TR, McDonald RA, et al. Leukocyte recruitment during pulmonary Cryptococcus neoformans infection. Immunopharmacology 2000; 48:231.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/4\" class=\"nounderline abstract_t\">Goldman DL, Khine H, Abadi J, et al. Serologic evidence for Cryptococcus neoformans infection in early childhood. Pediatrics 2001; 107:E66.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/5\" class=\"nounderline abstract_t\">BAKER RD, HAUGEN RK. Tissue changes and tissue diagnosis in cryptococcosis; a study of 26 cases. Am J Clin Pathol 1955; 25:14.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/6\" class=\"nounderline abstract_t\">Baker RD. The primary pulmonary lymph node complex of crytptococcosis. Am J Clin Pathol 1976; 65:83.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/7\" class=\"nounderline abstract_t\">Campbell GD. Primary pulmonary cryptococcosis. Am Rev Respir Dis 1966; 94:236.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/8\" class=\"nounderline abstract_t\">Chu HQ, Li HP, He GJ. Analysis of 23 cases of pulmonary cryptococcosis. Chin Med J (Engl) 2004; 117:1425.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/9\" class=\"nounderline abstract_t\">Pappas PG, Perfect JR, Cloud GA, et al. Cryptococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapy. Clin Infect Dis 2001; 33:690.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/10\" class=\"nounderline abstract_t\">Chang WC, Tzao C, Hsu HH, et al. Pulmonary cryptococcosis: comparison of clinical and radiographic characteristics in immunocompetent and immunocompromised patients. Chest 2006; 129:333.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/11\" class=\"nounderline abstract_t\">Shirley RM, Baddley JW. Cryptococcal lung disease. Curr Opin Pulm Med 2009; 15:254.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/12\" class=\"nounderline abstract_t\">Menon A, Rajamani R. Giant 'cryptococcoma' of the lung. Br J Dis Chest 1976; 70:269.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/13\" class=\"nounderline abstract_t\">Mitchell DH, Sorrell TC. Pancoast's syndrome due to pulmonary infection with Cryptococcus neoformans variety gattii. Clin Infect Dis 1992; 14:1142.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/14\" class=\"nounderline abstract_t\">Starr JC, Che H, Montgomery J. Cryptococcal pneumonia simulating chronic eosinophilic pneumonia. South Med J 1995; 88:845.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/15\" class=\"nounderline abstract_t\">Mitsuoka S, Kanazawa H. Images in Thorax. An unique case of primary pulmonary cryptococcosis with extensive chest wall invasion. Thorax 2005; 60:86.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/16\" class=\"nounderline abstract_t\">McAllister CK, Davis CE Jr, Ognibene AJ, Carpenter JL. Cryptococcal pleuro-pulmonary disease: infection of the pleural fluid in the absence of disseminated cryptococcosis. Case report. Mil Med 1984; 149:684.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/17\" class=\"nounderline abstract_t\">Young EJ, Hirsh DD, Fainstein V, Williams TW. Pleural effusions due to Cryptococcus neoformans: a review of the literature and report of two cases with cryptococcal antigen determinations. Am Rev Respir Dis 1980; 121:743.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/18\" class=\"nounderline abstract_t\">Zlupko GM, Fochler FJ, Goldschmidt ZH. Pulmonary cryptococcosis presenting with multiple pulmonary nodules. Chest 1980; 77:575.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/19\" class=\"nounderline abstract_t\">Lindell RM, Hartman TE, Nadrous HF, Ryu JH. Pulmonary cryptococcosis: CT findings in immunocompetent patients. Radiology 2005; 236:326.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/20\" class=\"nounderline abstract_t\">Yang CJ, Hwang JJ, Wang TH, et al. Clinical and radiographic presentations of pulmonary cryptococcosis in immunocompetent patients. Scand J Infect Dis 2006; 38:788.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/21\" class=\"nounderline abstract_t\">Hunt KK, Enquist RW, Bowen TE. Multiple pulmonary nodules with central cavitation. Chest 1976; 69:529.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/22\" class=\"nounderline abstract_t\">Feigin DS. Pulmonary cryptococcosis: radiologic-pathologic correlates of its three forms. AJR Am J Roentgenol 1983; 141:1262.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/23\" class=\"nounderline abstract_t\">Khoury MB, Godwin JD, Ravin CE, et al. Thoracic cryptococcosis: immunologic competence and radiologic appearance. AJR Am J Roentgenol 1984; 142:893.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/24\" class=\"nounderline abstract_t\">Murata K, Khan A, Herman PG. Pulmonary parenchymal disease: evaluation with high-resolution CT. Radiology 1989; 170:629.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/25\" class=\"nounderline abstract_t\">Fox DL, M&uuml;ller NL. Pulmonary cryptococcosis in immunocompetent patients: CT findings in 12 patients. AJR Am J Roentgenol 2005; 185:622.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/26\" class=\"nounderline abstract_t\">Baddley JW, Perfect JR, Oster RA, et al. Pulmonary cryptococcosis in patients without HIV infection: factors associated with disseminated disease. Eur J Clin Microbiol Infect Dis 2008; 27:937.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/27\" class=\"nounderline abstract_t\">Perfect JR, Dismukes WE, Dromer F, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america. Clin Infect Dis 2010; 50:291.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/28\" class=\"nounderline abstract_t\">Vilchez RA, Linden P, Lacomis J, et al. Acute respiratory failure associated with pulmonary cryptococcosis in non-aids patients. Chest 2001; 119:1865.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/29\" class=\"nounderline abstract_t\">Aberg JA, Mundy LM, Powderly WG. Pulmonary cryptococcosis in patients without HIV infection. Chest 1999; 115:734.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/30\" class=\"nounderline abstract_t\">Meyohas MC, Roux P, Bollens D, et al. Pulmonary cryptococcosis: localized and disseminated infections in 27 patients with AIDS. Clin Infect Dis 1995; 21:628.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/31\" class=\"nounderline abstract_t\">Kerkering TM, Duma RJ, Shadomy S. The evolution of pulmonary cryptococcosis: clinical implications from a study of 41 patients with and without compromising host factors. Ann Intern Med 1981; 94:611.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/32\" class=\"nounderline abstract_t\">Dromer F, Mathoulin-P&eacute;lissier S, Launay O, et al. Determinants of disease presentation and outcome during cryptococcosis: the CryptoA/D study. PLoS Med 2007; 4:e21.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/33\" class=\"nounderline abstract_t\">Thompson GR 3rd, Rendon A, Ribeiro Dos Santos R, et al. Isavuconazole Treatment of Cryptococcosis and Dimorphic Mycoses. Clin Infect Dis 2016; 63:356.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/34\" class=\"nounderline abstract_t\">Whitley TH, Graybill JR, Alford RH. Pulmonary cryptococcosis in chronic lymphocytic leukemia. South Med J 1976; 69:33.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/35\" class=\"nounderline abstract_t\">Kramer M, Corrado ML, Bacci V, et al. Pulmonary cryptococcosis and Cushing's syndrome. Arch Intern Med 1983; 143:2179.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/36\" class=\"nounderline abstract_t\">Finke R, Strobel ES, Kroepelin T, et al. Disseminated cryptococcosis in a patient with malignant lymphoma. Mycoses 1988; Suppl 1:102.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/37\" class=\"nounderline abstract_t\">Christoph I. Pulmonary Cryptococcus neoformans and disseminated Nocardia brasiliensis in an immunocompromised host. Case report. N C Med J 1990; 51:219.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/38\" class=\"nounderline abstract_t\">Cameron ML, Bartlett JA, Gallis HA, Waskin HA. Manifestations of pulmonary cryptococcosis in patients with acquired immunodeficiency syndrome. Rev Infect Dis 1991; 13:64.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/39\" class=\"nounderline abstract_t\">Arend SM, Kuijper EJ, Allaart CF, et al. Cavitating pneumonia after treatment with infliximab and prednisone. Eur J Clin Microbiol Infect Dis 2004; 23:638.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/40\" class=\"nounderline abstract_t\">Sun HY, Wagener MM, Singh N. Cryptococcosis in solid-organ, hematopoietic stem cell, and tissue transplant recipients: evidence-based evolving trends. Clin Infect Dis 2009; 48:1566.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/41\" class=\"nounderline abstract_t\">Kanj SS, Welty-Wolf K, Madden J, et al. Fungal infections in lung and heart-lung transplant recipients. Report of 9 cases and review of the literature. Medicine (Baltimore) 1996; 75:142.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/42\" class=\"nounderline abstract_t\">Visnegarwala F, Graviss EA, Lacke CE, et al. Acute respiratory failure associated with cryptococcosis in patients with AIDS: analysis of predictive factors. Clin Infect Dis 1998; 27:1231.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/43\" class=\"nounderline abstract_t\">Singh N, Alexander BD, Lortholary O, et al. Cryptococcus neoformans in organ transplant recipients: impact of calcineurin-inhibitor agents on mortality. J Infect Dis 2007; 195:756.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/44\" class=\"nounderline abstract_t\">Shaariah W, Morad Z, Suleiman AB. Cryptococcosis in renal transplant recipients. Transplant Proc 1992; 24:1898.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/45\" class=\"nounderline abstract_t\">Wasser L, Talavera W. Pulmonary cryptococcosis in AIDS. Chest 1987; 92:692.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/46\" class=\"nounderline abstract_t\">Clark RA, Greer DL, Valainis GT, Hyslop NE. Cryptococcus neoformans pulmonary infection in HIV-1-infected patients. J Acquir Immune Defic Syndr 1990; 3:480.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/47\" class=\"nounderline abstract_t\">Jensen WA, Rose RM, Hammer SM, Karchmer AW. Serologic diagnosis of focal pneumonia caused by Cryptococcus neoformans. Am Rev Respir Dis 1985; 132:189.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/48\" class=\"nounderline abstract_t\">Chanock SJ, Toltzis P, Wilson C. Cross-reactivity between Stomatococcus mucilaginosus and latex agglutination for cryptococcal antigen. Lancet 1993; 342:1119.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/49\" class=\"nounderline abstract_t\">McManus EJ, Jones JM. Detection of a Trichosporon beigelii antigen cross-reactive with Cryptococcus neoformans capsular polysaccharide in serum from a patient with disseminated Trichosporon infection. J Clin Microbiol 1985; 21:681.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/50\" class=\"nounderline abstract_t\">Westerink MA, Amsterdam D, Petell RJ, et al. Septicemia due to DF-2. Cause of a false-positive cryptococcal latex agglutination result. Am J Med 1987; 83:155.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/51\" class=\"nounderline abstract_t\">Tanner DC, Weinstein MP, Fedorciw B, et al. Comparison of commercial kits for detection of cryptococcal antigen. J Clin Microbiol 1994; 32:1680.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/52\" class=\"nounderline abstract_t\">Singh N, Alexander BD, Lortholary O, et al. Pulmonary cryptococcosis in solid organ transplant recipients: clinical relevance of serum cryptococcal antigen. Clin Infect Dis 2008; 46:e12.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/53\" class=\"nounderline abstract_t\">Malabonga VM, Basti J, Kamholz SL. Utility of bronchoscopic sampling techniques for cryptococcal disease in AIDS. Chest 1991; 99:370.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/54\" class=\"nounderline abstract_t\">Friedman EP, Miller RF, Severn A, et al. Cryptococcal pneumonia in patients with the acquired immunodeficiency syndrome. Clin Radiol 1995; 50:756.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/55\" class=\"nounderline abstract_t\">Perfect JR, Marr KA, Walsh TJ, et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis 2003; 36:1122.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/56\" class=\"nounderline abstract_t\">Raad II, Graybill JR, Bustamante AB, et al. Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections. Clin Infect Dis 2006; 42:1726.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/57\" class=\"nounderline abstract_t\">Dromer F, Mathoulin S, Dupont B, Laporte A. Epidemiology of cryptococcosis in France: a 9-year survey (1985-1993). French Cryptococcosis Study Group. Clin Infect Dis 1996; 23:82.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/58\" class=\"nounderline abstract_t\">Mart&iacute;nez E, Garc&iacute;a-Viejo MA, Marcos MA, et al. Discontinuation of secondary prophylaxis for cryptococcal meningitis in HIV-infected patients responding to highly active antiretroviral therapy. AIDS 2000; 14:2615.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/59\" class=\"nounderline abstract_t\">Ely EW, Peacock JE Jr, Haponik EF, Washburn RG. Cryptococcal pneumonia complicating pregnancy. Medicine (Baltimore) 1998; 77:153.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/60\" class=\"nounderline abstract_t\">Costeas PA, Koumouli A, Giantsiou-Kyriakou A, et al. Th2/Th3 cytokine genotypes are associated with pregnancy loss. Hum Immunol 2004; 65:135.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/61\" class=\"nounderline abstract_t\">Annapureddy SR, Masterson SW, David HG, Greig JR. Post partum osteomyelitis due to Cryptococcus neoformans. Scand J Infect Dis 2007; 39:354.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/62\" class=\"nounderline abstract_t\">Singh N, Perfect JR. Immune reconstitution syndrome and exacerbation of infections after pregnancy. Clin Infect Dis 2007; 45:1192.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/63\" class=\"nounderline abstract_t\">Mitchell TG, Perfect JR. Cryptococcosis in the era of AIDS--100 years after the discovery of Cryptococcus neoformans. Clin Microbiol Rev 1995; 8:515.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/64\" class=\"nounderline abstract_t\">Ding YG, Fang H. Edematous erythema, subcutaneous plaques, and severe pain in the lower extremities in an immunocompromised patient. JAMA 2013; 309:1632.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/65\" class=\"nounderline abstract_t\">Neuville S, Dromer F, Morin O, et al. Primary cutaneous cryptococcosis: a distinct clinical entity. Clin Infect Dis 2003; 36:337.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/66\" class=\"nounderline abstract_t\">Behrman RE, Masci JR, Nicholas P. Cryptococcal skeletal infections: case report and review. Rev Infect Dis 1990; 12:181.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/67\" class=\"nounderline abstract_t\">Crump JR, Elner SG, Elner VM, Kauffman CA. Cryptococcal endophthalmitis: case report and review. Clin Infect Dis 1992; 14:1069.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/68\" class=\"nounderline abstract_t\">Larsen RA, Bozzette S, McCutchan JA, et al. Persistent Cryptococcus neoformans infection of the prostate after successful treatment of meningitis. California Collaborative Treatment Group. Ann Intern Med 1989; 111:125.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/69\" class=\"nounderline abstract_t\">Sun HY, Alexander BD, Lortholary O, et al. Unrecognized pretransplant and donor&#8208;derived cryptococcal disease in organ transplant recipients. Clin Infect Dis 2010; 51:1062.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/70\" class=\"nounderline abstract_t\">Singh N, Husain S, De Vera M, et al. Cryptococcus neoformans Infection in Patients With Cirrhosis, Including Liver Transplant Candidates. Medicine (Baltimore) 2004; 83:188.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/71\" class=\"nounderline abstract_t\">Singh N, Lortholary O, Alexander BD, et al. Antifungal management practices and evolution of infection in organ transplant recipients with cryptococcus neoformans infection. Transplantation 2005; 80:1033.</a></li><li><a href=\"https://www.uptodate.com/contents/cryptococcus-neoformans-infection-outside-the-central-nervous-system/abstract/72\" class=\"nounderline abstract_t\">Singh N, Gayowski T, Marino IR. Successful treatment of disseminated cryptococcosis in a liver transplant recipient with fluconazole and flucytosine, an all oral regimen. Transpl Int 1998; 11:63.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 2421 Version 21.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H29\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">PULMONARY INFECTION IN IMMUNOCOMPETENT ADULTS</a><ul><li><a href=\"#H3\" id=\"outline-link-H3\">Clinical manifestations</a></li><li><a href=\"#H4\" id=\"outline-link-H4\">Diagnosis</a><ul><li><a href=\"#H5\" id=\"outline-link-H5\">- Culture and histology</a></li><li><a href=\"#H6\" id=\"outline-link-H6\">- Cryptococcal antigen</a></li><li><a href=\"#H7\" id=\"outline-link-H7\">- Radiography</a></li><li><a href=\"#H8\" id=\"outline-link-H8\">- Lumbar puncture</a></li></ul></li><li><a href=\"#H9\" id=\"outline-link-H9\">Treatment</a><ul><li><a href=\"#H10\" id=\"outline-link-H10\">- Antifungal therapy</a></li><li><a href=\"#H1029509529\" id=\"outline-link-H1029509529\">- Surgery</a></li></ul></li></ul></li><li><a href=\"#H11\" id=\"outline-link-H11\">PULMONARY INFECTION IN IMMUNOCOMPROMISED ADULTS</a><ul><li><a href=\"#H12\" id=\"outline-link-H12\">Clinical manifestations</a><ul><li><a href=\"#H13\" id=\"outline-link-H13\">- HIV-negative patients</a></li><li><a href=\"#H14\" id=\"outline-link-H14\">- HIV-positive patients</a></li></ul></li><li><a href=\"#H15\" id=\"outline-link-H15\">Diagnosis</a><ul><li><a href=\"#H16\" id=\"outline-link-H16\">- Cryptococcal antigen</a></li><li><a href=\"#H17\" id=\"outline-link-H17\">- Culture and histology</a></li><li><a href=\"#H18\" id=\"outline-link-H18\">- Radiography</a></li><li><a href=\"#H19\" id=\"outline-link-H19\">- Lumbar puncture</a></li></ul></li><li><a href=\"#H20\" id=\"outline-link-H20\">Treatment</a><ul><li><a href=\"#H21\" id=\"outline-link-H21\">- Antifungal therapy</a></li><li><a href=\"#H951399052\" id=\"outline-link-H951399052\">- Surgery</a></li></ul></li></ul></li><li><a href=\"#H24\" id=\"outline-link-H24\">PULMONARY INFECTION IN PREGNANT WOMEN</a></li><li><a href=\"#H25\" id=\"outline-link-H25\">PULMONARY INFECTION IN CHILDREN</a></li><li><a href=\"#H26\" id=\"outline-link-H26\">NONMENINGEAL, NONPULMONARY CRYPTOCOCCOSIS</a><ul><li><a href=\"#H27\" id=\"outline-link-H27\">Clinical manifestations</a></li><li><a href=\"#H28\" id=\"outline-link-H28\">Treatment</a></li></ul></li><li><a href=\"#H29\" id=\"outline-link-H29\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"ID/2421|DiagnosticImage\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"DIAGNOSTIC IMAGES\">DIAGNOSTIC IMAGES</a></div><ul><li><a href=\"image.htm?imageKey=ID/64815\" class=\"graphic graphic_diagnosticimage\">- Chest CT cryptococcal pneumonia</a></li></ul></li><li><div id=\"ID/2421|PIC\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"PICTURES\">PICTURES</a></div><ul><li><a href=\"image.htm?imageKey=ID/64561\" class=\"graphic graphic_picture\">- Crypto H and E</a></li><li><a href=\"image.htm?imageKey=DERM/69214\" class=\"graphic graphic_picture\">- Disseminated cryptococcosis - papules</a></li></ul></li><li><div id=\"ID/2421|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=ID/82028\" class=\"graphic graphic_table\">- Rx nonmeningeal crypto</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-cryptococcus-neoformans-meningoencephalitis-in-hiv-seronegative-patients\" class=\"medical medical_review\">Clinical manifestations and diagnosis of Cryptococcus neoformans meningoencephalitis in HIV-seronegative patients</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-presentation-and-diagnosis-of-pneumocystis-pulmonary-infection-in-hiv-infected-patients\" class=\"medical medical_review\">Clinical presentation and diagnosis of Pneumocystis pulmonary infection in HIV-infected patients</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=cryptococcus-gattii-infection-clinical-features-and-diagnosis\" class=\"medical medical_review\">Cryptococcus gattii infection: Clinical features and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=cryptococcus-gattii-infection-microbiology-epidemiology-and-pathogenesis\" class=\"medical medical_review\">Cryptococcus gattii infection: Microbiology, epidemiology, and pathogenesis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=cryptococcus-gattii-infection-treatment\" class=\"medical medical_review\">Cryptococcus gattii infection: Treatment</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=cryptococcus-neoformans-treatment-of-meningoencephalitis-and-disseminated-infection-in-hiv-seronegative-patients\" class=\"medical medical_review\">Cryptococcus neoformans: Treatment of meningoencephalitis and disseminated infection in HIV seronegative patients</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=epidemiology-clinical-manifestations-and-diagnosis-of-cryptococcus-neoformans-meningoencephalitis-in-hiv-infected-patients\" class=\"medical medical_review\">Epidemiology, clinical manifestations, and diagnosis of Cryptococcus neoformans meningoencephalitis in HIV-infected patients</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=immune-reconstitution-inflammatory-syndrome\" class=\"medical medical_review\">Immune reconstitution inflammatory syndrome</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=microbiology-and-epidemiology-of-cryptococcus-neoformans-infection\" class=\"medical medical_review\">Microbiology and epidemiology of Cryptococcus neoformans infection</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-cryptococcus-neoformans-meningoencephalitis-in-hiv-infected-patients\" class=\"medical medical_review\">Treatment of Cryptococcus neoformans meningoencephalitis in HIV-infected patients</a></li></ul></div></div>","javascript":null}